Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

On This Page

All Headings will automatically be pulled in to this list.
Do not edit the content on this template.

Major Programs

Staff List

Grid View

Name, Email, Phone	Room	Group(s)/Office
Asefa, Wosene wosene.asefa@nih.gov 240-276-6422	5E504	Program Support Assistant \| Chemopreventive Agent Development
Biswas, Kajal, Ph.D. kajal.biswas2@nih.gov 240-276-5614	5E540	Program Officer \| Chemopreventive Agent Development
Boring, Daniel, R.Ph., Ph.D. [C] daniel.boring@nih.gov		Contractor \| Chemopreventive Agent Development
Cholewa, Brian, Ph.D. brian.cholewa@nih.gov 240-276-7545	5E446	Deputy Chief \| Chemopreventive Agent Development
Clifford, John, Ph.D. john.clifford@nih.gov 202-235-4482	5E430	Program Officer \| Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D. vignesh.gunasekharan@nih.gov 240-276-5814	5E438	Program Officer \| Chemopreventive Agent Development
Mohammed, Altaf, Ph.D. altaf.mohammed@nih.gov 240-276-6082	5E542	Deputy Chief \| Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S. ancy.nalli@nih.gov 202-276-5265	5E536	Program Officer \| Chemopreventive Agent Development
Sei, Shizuko, M.D. shizuko.sei@nih.gov 240-276-5005	5E452	Co-Chief \| Chemopreventive Agent Development
Shoemaker, Robert, Ph.D. robert.shoemaker@nih.gov 240-276-7077	5E454	Co-Chief \| Chemopreventive Agent Development Acting Chief \| Nutritional Science
Vlad, Anda, M.D., Ph.D. anda.vlad@nih.gov 240-276-6422	5E538	Program Officer \| Chemopreventive Agent Development

Grants

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Lindau, Stacy Tessler	University Of Chicago United States	Bionic Breast Project: A Neuroprosthesis to Restore Touch Sensation and Reduce Chronic Pain After Mastectomy	5R01CA281301-03	Marjorie Perloff, M.D.
Lipkin, Steven M	Weill Medical Coll Of Cornell Univ United States	CAP-IT Center for LNP RNA Immunoprevention	5U54CA272688-03	John Clifford, Ph.D.
Mcguire, Andrew	Fred Hutchinson Cancer Center United States	Rational Vaccine Design to prevent HIV-Associated Lymphoma	5R01CA285227-02
Morin, Olivier	University Of California, San Francisco United States	Development of a Personalized Voxel-wise Prediction of Brain Metastases using Multi-Parametric MR Imaging to Reduce Treatment Toxicity	1R01CA292043-01A1	Marjorie Perloff, M.D.
Moses, John Edward	Cold Spring Harbor Laboratory United States	Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic Cancer	1UG3CA290364-01A1	Altaf Mohammed, Ph.D.
Muzumdar, Mandar Deepak	Yale University United States	Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics	1R01CA296916-01
Nelson, Randy J.	West Virginia University United States	Mechanism Underlying Sleep Disruption by Mammary Tumors	5R21CA276027-02	Marjorie Perloff, M.D.
Panigrahy, Dipak	Beth Israel Deaconess Medical Center United States	Control of cancer cachexia via stimulation of resolution of inflammation	5R01CA276107-02	Marjorie Perloff, M.D.
Park, Youngkyu	Cold Spring Harbor Laboratory United States	Preclinical Models for Cancer Therapeutic Development	5R50CA211506-09	Marjorie Perloff, M.D.
Pena, Maria Marjorette	University Of South Carolina At Columbia United States	The Role of Early Life Exposure to Antibiotics on Risk of Early Onset Colorectal Cancer	1R21CA281729-01A1
Peters, Jeffrey M	Pennsylvania State University, The United States	Unique targeting of PPARβ/δ regulation for cancer prevention and therapy	5R01CA239256-05	Marjorie Perloff, M.D.
Pyter, Leah M	Ohio State University United States	Chemotherapy-induced circadian master clock disruptions and fatigue	3R01CA270372-03S1	Marjorie Perloff, M.D.
Robertson, Gavin P.	Pennsylvania State Univ Hershey Med Ctr United States	Targeting Aldehyde Dehydrogenase for Cancer Prevention	5R01CA241148-05
Sands, Stephen Alan	Sloan-Kettering Inst Can Research United States	Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR)	5R01CA283045-02	Marjorie Perloff, M.D.
Shirwan, Haval	University Of Missouri-Columbia United States	Developing a novel agonist of CD137 for cancer immunoprevention	5UG3CA290305-02	Altaf Mohammed, Ph.D.